One To Watch

Tarsier Pharma

An Israel-based clinical-stage biotech pursuing steroid-free, immune-tolerance therapies for blinding ocular diseases, with a Phase III program in non-infectious uveitis anchored by an FDA-agreed Special Protocol Assessment.

Company Overview

An Israel-based clinical-stage biotech pursuing steroid-free, immune-tolerance therapies for blinding ocular diseases, Tarsier Pharma is building its pipeline around dazdotuftide, a single platform molecule deployed in two distinct ocular formulations. The company's thesis is that targeting immune tolerance from within the immune system — rather than broadly suppressing it with corticosteroids — can deliver durable inflammation control without the intraocular pressure risks and cataract sequelae that make chronic steroid use untenable. Its lead program, TRS01, has secured FDA Special Protocol Assessment agreement for a Phase III trial, giving it a clear, FDA-endorsed pathway to a registration-enabling readout. Tarsier listed on Nasdaq under the ticker TARX in 2026, raising capital specifically to advance that pivotal program.

Headquarters and Global Presence

Tarsier Pharma is headquartered in Israel and is pursuing its clinical and regulatory activities in the United States, where it has engaged the FDA for SPA designation and is listing on Nasdaq. Its SEC filings confirm active US operations in connection with the 2026 IPO.

Founding and History

Tarsier Pharma was founded by Daphne Haim-Langford, Ph.D., who remains CEO, reflecting the founder-led model common among Israeli clinical-stage biotechs. The company advanced dazdotuftide through early clinical stages before securing FDA SPA agreement for the Tarsier-04 Phase III trial — a notable regulatory milestone that de-risks the trial design. In May 2026, the company set terms for a $45 million Nasdaq IPO, pricing 5 million shares at $8–$10, implying a fully diluted market capitalization of approximately $294 million at the midpoint.

Therapy Areas and Focus

Tarsier's primary focus is ocular inflammatory disease — specifically non-infectious anterior uveitis, uveitic glaucoma, posterior and intermediate uveitis, and panuveitis, conditions where recurrent inflammation can lead to irreversible vision loss. The company extends its ambition to retinal disease through TRS02, which targets diabetic macular edema, nonproliferative diabetic retinopathy, and dry age-related macular degeneration. The commercial logic is consistent across indications: chronic inflammatory ocular disease is managed today largely with corticosteroids or systemic immunosuppressants, both carrying significant long-term tolerability burdens. A steroid-free, locally delivered immune-tolerance agent with a clean safety profile would have a structurally differentiated position in each of these markets.

Technology Platforms and Modalities

Dazdotuftide is Tarsier's platform active ingredient, described as approaching inflammatory disease from within the immune system — inducing tolerance rather than blanket suppression. The key commercial insight is that the same molecule can be reformulated for entirely different anatomical targets: TRS01 is an eye drop for anterior segment disease, while TRS02 is an intravitreal injection reaching the posterior segment. This formulation flexibility allows Tarsier to pursue multiple high-value indications from a single pharmacological engine, reducing the science risk of pipeline expansion. Whether dazdotuftide's tolerance mechanism is meaningfully durable beyond the treatment period remains the central clinical question to be answered by the Phase III program.

Key Pipeline and Programs

TRS01 is an ocular solution formulation of dazdotuftide administered as eye drops, targeting non-infectious anterior uveitis and uveitic glaucoma. It is the lead asset and has received FDA Special Protocol Assessment agreement for the Tarsier-04 Phase III trial — meaning the FDA has prospectively agreed that the trial design and endpoints are adequate to support a marketing application if the primary endpoint is met. That alignment materially reduces regulatory execution risk relative to a Phase III proceeding without SPA. TRS02 is an intravitreal injection formulation of dazdotuftide aimed at the posterior segment, with a broader set of target indications including posterior, intermediate, and panuveitis, diabetic macular edema, nonproliferative diabetic retinopathy, and dry AMD. TRS02 represents a longer-dated but substantially larger commercial opportunity, given the scale of the diabetic eye disease and dry AMD markets. Both programs rest on the same dazdotuftide mechanism, with formulation and route of administration tailored to their respective anatomical targets.

Recent Developments

In May 2026, Tarsier set terms for its Nasdaq IPO under ticker TARX, seeking to raise $45 million through the sale of 5 million shares at $8–$10, implying a fully diluted market cap of approximately $294 million at midpoint. The IPO proceeds are earmarked for advancement of the Phase III ocular program. The FDA SPA agreement for the Tarsier-04 trial in non-infectious anterior uveitis and uveitic glaucoma represents the most substantive recent regulatory milestone, providing design certainty ahead of the pivotal readout.

Key Personnel

Daphne Haim-Langford, Ph.D. serves as Founder and CEO. She has led the company from inception through Phase III entry and the 2026 public listing, and her scientific background underpins the dazdotuftide immune-tolerance rationale. Further executive appointments beyond the founder-CEO have not been publicly detailed in available sources.

Strategic Partnerships

No major licensing deals or co-development partnerships have been disclosed in available sources. Tarsier appears to be advancing its pipeline independently, using the $45 million IPO proceeds to fund the Phase III program rather than relying on a large-pharma partner for capital or development resources.

FAQ Section

Tarsier's decision to list on Nasdaq and raise $45 million independently suggests the company believes it can retain full value through Phase III readout rather than diluting upside via a licensing deal at the current stage. With FDA SPA agreement already in hand for the Tarsier-04 trial, the risk profile is materially lower than a pre-SPA Phase III entry, which strengthens the case for maintaining independence. Proceeds are specifically earmarked for the pivotal program, indicating a focused deployment of capital.

Non-infectious uveitis involves aberrant immune activation in the eye, and the standard of care — corticosteroids and systemic immunosuppressants — suppresses inflammation broadly, generating well-documented side effects including steroid-induced ocular hypertension, cataract formation, and systemic toxicity. An immune-tolerance mechanism targets the upstream dysregulation rather than downstream inflammation, with the goal of achieving durable disease control and a safer long-term tolerability profile. If dazdotuftide can reset immune activity rather than suppress it, the therapeutic durability argument becomes compelling for a chronic, relapsing disease.

The steroid-free, immune-tolerance mechanism is the primary point of differentiation — current locally administered options for anterior uveitis are predominantly corticosteroid drops or steroid implants, which carry pressure and cataract risks that restrict chronic use. Dazdotuftide's formulation flexibility is also notable: deploying the same active molecule as both a topical drop and an intravitreal injection allows Tarsier to address anterior and posterior segment disease without developing a separate pharmacological entity. The FDA SPA for Tarsier-04 further differentiates the program by confirming that the trial design is registration-grade before pivotal enrollment begins.

TRS01 is a topical eye drop formulation of dazdotuftide for non-infectious anterior uveitis, including uveitic glaucoma. The FDA Special Protocol Assessment for the Tarsier-04 Phase III trial means the agency has reviewed and agreed — prospectively — that the trial's design, endpoints, and statistical analysis plan are adequate to support a New Drug Application if the primary endpoint is met. This is a meaningful de-risking step: it eliminates the scenario where a company completes a Phase III only to receive FDA feedback that the trial was not designed to support approval.

TRS01 addresses the anterior segment — uveitis and uveitic glaucoma — while TRS02, the intravitreal formulation, targets the far larger posterior segment market: posterior, intermediate, and panuveitis, diabetic macular edema, nonproliferative diabetic retinopathy, and dry AMD. Diabetic macular edema and dry AMD alone represent multi-billion-dollar annual markets with significant unmet need, particularly dry AMD where approved treatment options remain limited. TRS02 is a longer-dated program, but the shared molecular platform means preclinical and toxicology work for dazdotuftide informs both assets.

Tarsier is entering the pivotal Phase III stage for TRS01 in non-infectious anterior uveitis, with the Tarsier-04 trial design validated by FDA SPA agreement. The company is a clinical-stage entity that completed its Nasdaq IPO in 2026, raising the capital needed to execute the Phase III program. The primary near-term milestone is enrollment and progression of the Tarsier-04 trial; TRS02 appears to be at an earlier stage of clinical development, with its posterior-segment indications constituting a longer-dated pipeline opportunity.

The investment case hinges on a narrow set of execution-dependent events. Key watchpoints include:

Tarsier-04 enrollment pace and any interim safety signals from the Phase III trial in anterior uveitis.
The durability question: whether dazdotuftide's tolerance mechanism produces sustained remission after treatment, or requires ongoing dosing, will define the commercial and clinical differentiation story.
TRS02 development timelines — progress toward a clinical readout in diabetic macular edema or dry AMD would significantly expand the addressable market thesis.
Post-IPO cash runway: with $45 million raised at a ~$294 million fully diluted valuation, execution against the Phase III timeline without additional dilutive financing will be closely watched.
The competitive landscape in uveitis is not static — any Phase III success by a rival steroid-sparing agent could compress the window for differentiated positioning.

Want to Update your Company's Profile?